Deshan Li

2.4k total citations
80 papers, 2.0k citations indexed

About

Deshan Li is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Deshan Li has authored 80 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 9 papers in Genetics and 9 papers in Immunology. Recurrent topics in Deshan Li's work include Fibroblast Growth Factor Research (58 papers), Kruppel-like factors research (37 papers) and Epigenetics and DNA Methylation (23 papers). Deshan Li is often cited by papers focused on Fibroblast Growth Factor Research (58 papers), Kruppel-like factors research (37 papers) and Epigenetics and DNA Methylation (23 papers). Deshan Li collaborates with scholars based in China, Japan and United States. Deshan Li's co-authors include Guiping Ren, Wenfei Wang, Siming Li, Yin-Hang Yu, Shunji Suzuki, Ken‐ichi Machida, Qingyan Yuan, Yunye Liu, Fuliang Bai and Junyan Li and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Oncogene.

In The Last Decade

Deshan Li

78 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deshan Li China 23 1.2k 249 228 193 176 80 2.0k
Thomas Neumann Germany 29 826 0.7× 166 0.7× 94 0.4× 199 1.0× 350 2.0× 97 2.6k
Meidong Liu China 24 973 0.8× 363 1.5× 122 0.5× 149 0.8× 148 0.8× 88 2.2k
Na Liu China 24 782 0.7× 222 0.9× 240 1.1× 125 0.6× 145 0.8× 98 2.1k
Chunxu Wang China 19 454 0.4× 369 1.5× 345 1.5× 122 0.6× 91 0.5× 57 1.7k
Takeshi Hori Japan 27 698 0.6× 328 1.3× 76 0.3× 797 4.1× 70 0.4× 151 2.7k
Cong Ma China 28 1.7k 1.4× 279 1.1× 37 0.2× 233 1.2× 264 1.5× 142 3.2k
Hitoshi Amano Japan 20 1.3k 1.1× 36 0.1× 120 0.5× 103 0.5× 63 0.4× 79 2.1k
Ye Cheng China 24 557 0.5× 111 0.4× 210 0.9× 68 0.4× 32 0.2× 105 1.7k
Nan Lü China 28 1.3k 1.1× 349 1.4× 26 0.1× 213 1.1× 215 1.2× 114 2.9k
Patricia Prieto Spain 17 306 0.3× 88 0.4× 104 0.5× 106 0.5× 58 0.3× 37 880

Countries citing papers authored by Deshan Li

Since Specialization
Citations

This map shows the geographic impact of Deshan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deshan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deshan Li more than expected).

Fields of papers citing papers by Deshan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deshan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deshan Li. The network helps show where Deshan Li may publish in the future.

Co-authorship network of co-authors of Deshan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Deshan Li. A scholar is included among the top collaborators of Deshan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deshan Li. Deshan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Yu, Yanyan Zhu, Deshan Li, et al.. (2025). Pharmacologically targeting cGAS-STING: a novel therapeutic opportunities in kidney diseases. European Journal of Pharmacology. 1007. 178296–178296. 1 indexed citations
2.
Kang, Kai, et al.. (2021). Therapeutic effect and mechanism of combined use of FGF21 and insulin on diabetic nephropathy. Archives of Biochemistry and Biophysics. 713. 109063–109063. 13 indexed citations
3.
Sun, Xu, Yuanyuan Jiang, Guanying Wang, et al.. (2020). FGF21 Enhances Therapeutic Efficacy and Reduces Side Effects of Dexamethasone in Treatment of Rheumatoid Arthritis. Inflammation. 44(1). 249–260. 11 indexed citations
4.
Zhang, Ruonan, et al.. (2020). Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes. Naunyn-Schmiedeberg s Archives of Pharmacology. 394(5). 1031–1043. 4 indexed citations
5.
Tao, Zhang Jiang, et al.. (2019). Phantom study of the influence of CareDose 4D and Care kV on CT pulmonary ground glass nodule with respect to image quality and radiation dose. Zhonghua fangshe yixue yu fanghu zazhi. 39(7). 534–538. 2 indexed citations
6.
Guo, Xiaochen, Xiangxiang Wang, Qingyan Yuan, et al.. (2019). Evaluation of a cell model expressing βKlotho for screening FGF21 analogues. Cytotechnology. 71(5). 1033–1041. 1 indexed citations
7.
Dong, Na, Xinran Li, Chenyu Xue, et al.. (2019). Astragalus polysaccharides attenuated inflammation and balanced the gut microflora in mice challenged with Salmonella typhimurium. International Immunopharmacology. 74. 105681–105681. 73 indexed citations
8.
Wang, Nan, Shuai Li, Xiaochen Guo, et al.. (2018). Fibroblast growth factor 21 improves glucose homeostasis partially via down-regulation of Na+-d-glucose cotransporter SGLT1 in the small intestine. Biomedicine & Pharmacotherapy. 109. 1070–1077. 11 indexed citations
9.
Li, Shuai, Xiaochen Guo, Teng Zhang, et al.. (2017). Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway. Biomedicine & Pharmacotherapy. 93. 695–704. 22 indexed citations
10.
Yu, Dan, Xianlong Ye, Qiang Wu, et al.. (2017). FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. Biomedicine & Pharmacotherapy. 89. 751–760. 16 indexed citations
11.
Ye, Xianlong, Jianying Qi, Dan Yu, et al.. (2017). Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. Journal of Diabetes and its Complications. 31(4). 726–734. 24 indexed citations
12.
13.
Ye, Xianlong, Jianying Qi, Qiang Wu, et al.. (2016). Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity. European Journal of Pharmacology. 781. 198–208. 6 indexed citations
14.
Yu, Yin-Hang, Jinjiao He, Siming Li, et al.. (2016). Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. International Immunopharmacology. 38. 144–152. 135 indexed citations
15.
Xu, Pengfei, Yingjie Zhang, Liying Song, et al.. (2016). Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice. Biomedicine & Pharmacotherapy. 84. 97–105. 10 indexed citations
16.
Yu, Yin-Hang, Fuliang Bai, Wenfei Wang, et al.. (2015). Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacology Biochemistry and Behavior. 133. 122–131. 100 indexed citations
17.
Wang, Wenfei, Nan Zhang, Tingting Zhao, et al.. (2014). Inhibition of Tumor Growth by Polyarginine-Fused Mutant Cytosine Deaminase. Applied Biochemistry and Biotechnology. 175(3). 1633–1643. 3 indexed citations
18.
Ren, Guiping, Liming Xu, Qiuying Wang, et al.. (2014). Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model. International Immunopharmacology. 21(1). 119–127. 19 indexed citations
19.
Li, Deshan, et al.. (2013). Methoxy-Poly(ethylene glycol)-block-Poly(?-caprolactone) Bearing Pendant Aldehyde Groups as pH-Responsive Drug Delivery Carrier. Australian Journal of Chemistry. 66(12). 1576–1583. 7 indexed citations
20.
Robinson, Dan R., Hua‐Chien Chen, Deshan Li, et al.. (1998). Tyrosine kinase expression profiles of chicken erythro-progenitor cells and oncogene-transformed erythroblasts. Journal of Biomedical Science. 5(2). 93–100. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Neumann Breakdown of academic impact, for papers by Meidong Liu Breakdown of academic impact, for papers by Na Liu Breakdown of academic impact, for papers by Chunxu Wang Breakdown of academic impact, for papers by Takeshi Hori Breakdown of academic impact, for papers by Cong Ma Breakdown of academic impact, for papers by Hitoshi Amano Breakdown of academic impact, for papers by Ye Cheng Breakdown of academic impact, for papers by Nan Lü Breakdown of academic impact, for papers by Patricia Prieto
Rankless by CCL
2026